Mackenzie Financial
KPTI icon

Mackenzie Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Mackenzie Financial’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,054
Closed -$53.8K – 1570
2022
Q4 		$53.8K Buy
1,054
+134
+15% +$9.29K ﹤0.01% 1347
2022
Q3 		$75K Buy
920
+125
+16% +$9.34K ﹤0.01% 1333
2022
Q2 		$54K Buy
+795
New +$72.9K ﹤0.01% 1391
2020
Q2 		– Sell
-2,439
Closed -$703K – 1077
2020
Q1 		$703K Buy
2,439
+1,567
+180% +$432K ﹤0.01% 738
2019
Q4 		$251K Buy
+872
New +$189K ﹤0.01% 989

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mackenzie Financial's KPTI Position: Q1 2023 in Review

Mackenzie Financial sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 1,054 shares — an estimated $53.8K sold.

Mackenzie Financial first reported a position in KPTI in Q4 2019 and held it in 5 quarters. The position peaked at $703K in Q1 2020. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Mackenzie Financial reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 1,054 Karyopharm Therapeutics shares in Q1 2023, an estimated $53.8K.
  • Mackenzie Financial first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 5 quarters.
  • Mackenzie Financial's Karyopharm Therapeutics position peaked at $703K in Q1 2020.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.